Patents Issued in April 23, 2020
  • Publication number: 20200121600
    Abstract: The present invention provides a liposome useful as a vaccine adjuvant. More specifically, the present invention provides a liposome which comprises a lipid bilayer comprising dimyristoylphosphatidylcholine and egg phosphatidylglycerol and a conjugated compound in which a low-molecular weight compound enhancing the physiological activity of TLR7 is bound to squalene via a linker, said conjugated compound being encapsulated in the lipid bilayer.
    Type: Application
    Filed: March 28, 2018
    Publication date: April 23, 2020
    Inventor: Akihisa Fukushima
  • Publication number: 20200121601
    Abstract: The present application is directed to a cochleate composition including one or more cochleates and at least two antifungal compounds selected from amphotericin B, 5-flucytosine, fluconazole, ketoconazole, ravuconazole, albaconazole, itraconazole, posaconazole, isavuconazole and/or voriconazole. Methods of using the antifungal cochleate formulations are also disclosed.
    Type: Application
    Filed: July 12, 2017
    Publication date: April 23, 2020
    Applicant: Matinas BioPharma Nanotechnologies, Inc.
    Inventors: Raphael J. MANNINO, Ruying LU, Doug F. KLING
  • Publication number: 20200121602
    Abstract: Disclosed are targeted sub-50 nanometer nanoparticles suitable for delivering bioactive agents of interest, and related compositions, methods, and systems, which improve the manufacturing, stability, efficacy and other aspects of therapeutic nanoparticles.
    Type: Application
    Filed: November 26, 2018
    Publication date: April 23, 2020
    Inventor: Gretchen M. Unger
  • Publication number: 20200121603
    Abstract: Fine dry particulate adenosine compositions suitable for use in topical formulations, as well as methods of making the same, are provided. In the dry particulate adenosine composition, the adenosine active agent is associated with the particles, e.g., via entrapment in the pores of the particles and/or ionic binding and/or non-covalent binding to the surface of the particles and/or loosely associated with the particles. Also provided are topical formulations which include the dry particulate adenosine compositions of the invention, and methods of using the same.
    Type: Application
    Filed: October 11, 2019
    Publication date: April 23, 2020
    Inventor: Zahra Mansouri
  • Publication number: 20200121604
    Abstract: Solid formulations comprising a compound having formula (I) or a pharmaceutically acceptable salt thereof, and their use in the treatment of neurologic disorders (such as pantothenate kinase-associated neurodegeneration), are provided.
    Type: Application
    Filed: February 7, 2018
    Publication date: April 23, 2020
    Inventors: Dainius Macikenas, Kale Ruby
  • Publication number: 20200121605
    Abstract: Disclosed herein is anticancer composition comprising an anti-cancer agent and poly(lactic-co-glycolic acid) (PLGA) carrier thereof. Further disclosed herein is a method for treating a breast disorder in a subject in need thereof, comprising administering to the breast of a subject via an intraductal injection an effective amount of a composition comprising a therapeutic agent and a PLGA carrier thereof. In some aspects the carrier is a microsphere.
    Type: Application
    Filed: October 21, 2019
    Publication date: April 23, 2020
    Inventors: Omathanu Perumal, Mibin Kuruvilla Joseph, Joshua Reineke
  • Publication number: 20200121606
    Abstract: Provided are solid oral/per os formulations that include a single cannabinoid, combination of cannabinoids, cannabis extract and combination of cannabis plant constituents. Also provided are methods of making the formulations, as well as therapeutic applications in the treatment and alleviation of various human disorders and/or conditions.
    Type: Application
    Filed: December 20, 2019
    Publication date: April 23, 2020
    Applicants: GELPELL AG, SATIPHARM AG
    Inventors: Hagit SACKS, Tomas EDVINSSON
  • Publication number: 20200121607
    Abstract: The invention pertains to dispersible tablets comprising as active ingredient N-{3-[5-(2-Amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide, methanesulfonate salt, processes for preparing the same, and processes for using the same.
    Type: Application
    Filed: June 29, 2018
    Publication date: April 23, 2020
    Inventors: Nikos KARANIKOLOPOULOS, Paul Anthony GOULDING
  • Publication number: 20200121608
    Abstract: In certain embodiments, the present invention is directed to a solid controlled release dosage form comprising: a core comprising a first portion of an opioid analgesic dispersed in a first matrix material; and a shell encasing the core and comprising a second portion of the opioid analgesic dispersed in a second matrix material; wherein the amount of opioid analgesic released from the dosage form is proportional within 20% to elapsed time from 8 to 24 hours, as measured by an in-vitro dissolution in a USP Apparatus 1 (basket) at 100 rpm in 900 ml simulated gastric fluid without enzymes (SGF) at 37 C.
    Type: Application
    Filed: October 24, 2019
    Publication date: April 23, 2020
    Inventor: Haiyong Hugh Huang
  • Publication number: 20200121609
    Abstract: The present disclosure discloses a pH-sensitive starch-based microcapsule encapsulating a fat-soluble substance and a preparation method thereof, and belongs to the field of preparation of starch-based hydrogel microcapsules. The method of the present disclosure comprises performing acid hydrolysis on starch to obtain acid-hydrolyzed carboxymethyl starch, mixing the acid-hydrolyzed carboxymethyl starch with xanthan gum to obtain a compounded solution of starch and colloid, adding an emulsifier and the fat-soluble substance, emulsifying to obtain an emulsion, and drying to obtain the microcapsule.
    Type: Application
    Filed: December 19, 2019
    Publication date: April 23, 2020
    Inventors: Yan HONG, Min JIANG, Zhengbiao GU, Li CHENG, Zhaofeng LI, Caiming LI
  • Publication number: 20200121610
    Abstract: The invention discloses a composition comprising surface modified iron oxide nanoparticles with citric acid modified cyclodextrin with a hydrodynamic diameter of less than 10 nm and a hydrophobic molecule. The composition finds use in targeted delivery of a hydrophobic drug and as contrast agent in imaging applications.
    Type: Application
    Filed: October 25, 2019
    Publication date: April 23, 2020
    Applicant: COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH
    Inventors: Pattayil Joy, Jayaprabha Kunnoth Naduvilidam
  • Publication number: 20200121611
    Abstract: A patch comprising: a backing layer; and an adhesive layer, wherein the adhesive layer contains a mixture of a pharmaceutically acceptable acid addition salt of ropinirole and potassium hydrogen carbonate, and the mixture contains at least one selected from the group consisting of ropinirole and pharmaceutically acceptable acid addition salts thereof and potassium hydrogen carbonate.
    Type: Application
    Filed: February 19, 2018
    Publication date: April 23, 2020
    Applicant: HISAMITSU PHARMACEUTICAL CO., INC.
    Inventors: Hideaki OHASHI, Takito SHIMA, Kenji ISHIGAKI, Yasunari MICHINAKA
  • Publication number: 20200121612
    Abstract: An external patch that contains rupatadine as a second-generation antihistamine, has excellent plaster physical properties, good adhesion to applied skin, and good transdermal absorption of rupatadine as an active ingredient is provided. The external patch containing rupatadine uses an acrylic adhesive as an adhesive base. Specifically, the external patch containing rupatadine uses an acrylic adhesive as an adhesive base and further contains an organic acid having 2 to 7 carbon atoms as a solubilizer, a fatty acid ester as a softener, and/or a surfactant.
    Type: Application
    Filed: April 18, 2018
    Publication date: April 23, 2020
    Applicants: TEIKOKU SEIYAKU CO., LTD., J.URIACH Y COMPANIA S.A.
    Inventors: Satoshi KAWAKAMI, Manabu SOGABE
  • Publication number: 20200121613
    Abstract: A patch comprises a backing layer and an adhesive layer, wherein the adhesive layer contains at least one selected from the group consisting of butorphanol and pharmaceutically acceptable salts thereof, and contains a rubber-based adhesive base and a silicone-based adhesive base, and a mass ratio of the rubber-based adhesive base to the silicone-based adhesive base (the mass of the rubber-based adhesive base:the mass of silicone-based adhesive base) in the adhesive layer is 9.5:0.5 to 1.9:8.1.
    Type: Application
    Filed: April 19, 2018
    Publication date: April 23, 2020
    Applicant: HISAMITSU PHARMACEUTICAL CO., INC.
    Inventors: Kazuya KOMINAMI, Takito SHIMA, Naoyuki UCHIDA, Naoko FUJITA, Shigeo SUZUKI, Terumitsu KAIHO
  • Publication number: 20200121614
    Abstract: A flexible, transparent gel patch product contains a clear cannabinoid-infused hydrogel material in a gel-like phase. The gel patch product is comprised of several layers including a gel layer, removable tab and release liner. The removable tab provides a graspable surface to allow for the removal of the release liner from the gel patch and to facilitate handling of the gel patch during application to the skin. The tab may be comprised of a flat, double-coated paper or other suitable material, or a flexible, V-shaped member, and is removable by peeling after the gel patch is applied. The gel patch includes a transparent cover and a grid pattern may be printed on the backing layer to permit visualization of the underlying skin and measurement of any injury or wounds, for example.
    Type: Application
    Filed: September 16, 2019
    Publication date: April 23, 2020
    Applicant: Bluegrass Farmacueticals, LLC
    Inventor: David M. Tumey
  • Publication number: 20200121615
    Abstract: Provided herein are compositions, systems, and methods for causing weight loss and treating and/or preventing a disease or condition, such as obesity, diabetes, and cancer, with an agent or procedure that inhibits the TMA/FMO3/TMAO pathway in a subject.
    Type: Application
    Filed: June 19, 2018
    Publication date: April 23, 2020
    Inventors: Stanley L. Hazen, Jonathan Mark Brown
  • Publication number: 20200121616
    Abstract: The present invention provides compositions comprising a combination of cannabidiol (CBD) or a derivative thereof, and hyaluronic acid or a salt thereof; a phospholipid, and optionally a carrier, methods of using the compositions for treating inflammatory joint diseases, or pain or inflammation associated with such diseases, and methods for their preparation.
    Type: Application
    Filed: May 24, 2017
    Publication date: April 23, 2020
    Inventor: Tamir GEDO
  • Publication number: 20200121617
    Abstract: The present invention relates to methods of treating female reproductive tract irritation (such as pain and pruritus) or/and inflammation.
    Type: Application
    Filed: October 2, 2019
    Publication date: April 23, 2020
    Applicant: University of Rochester
    Inventors: David Foster, Megan L. Falsetta Wood, Richard P. Phipps
  • Publication number: 20200121618
    Abstract: Compounds, compositions, and methods for treatment of, or prophylaxis against, inflammation and/or oxidative stress are disclosed.
    Type: Application
    Filed: April 14, 2018
    Publication date: April 23, 2020
    Inventors: Guy M. MILLER, Jeffery K. TRIMMER, William D. SHRADER, Andrew W. HINMAN, Charles R. HOLST, Joey C. LATHAM, Joel J. BRUEGGER, Kevin P. MCCUSKER, Gozde ULAS, Dana DAVIS, Amanda H. KAHN-KIRBY, Edgar P. LEE, Stephanie A. MALONE, Steven J. RICHARDS, Matthew B. KLEIN
  • Publication number: 20200121619
    Abstract: The present invention relates to hydroxynorketamine for the use in the treatment of depression. In particular, the present invention concerns hydroxynorketamine for use in the treatment of depression, wherein hydroxynorketamine is administered in form of at least one prodrug, and wherein the at least one prodrug is orally administered in a modified-release dosage form. The prodrug is selected from (S)-Ketamine, (R)-Ketamine, (R,S)-Ketamine, (S)-Norketamine, (R)-Norketamine, (R,S)-Norketamine, (S)-Hydroxyketamine, (R)-Hydroxyketamine, (R,S)-Hydroxyketamine.
    Type: Application
    Filed: June 22, 2018
    Publication date: April 23, 2020
    Inventor: Helene REY
  • Publication number: 20200121620
    Abstract: The present invention relates to an agent for use in selectively killing one or more senescent cells, wherein said agent is selected from the following: a cardiac glycoside or alglycone, a focal adhesion kinase (FAK) inhibitor, an HMG-CoA reductase inhibitor, JFD00244, Cyclosporine, Tyrphostin AG879, Cantharidin, Diphenyleneiodonium chloride, Rottlerin, 2,3-Dimethoxy-1,4-naphthoquinone, LY-367,265, Rotenone, Idarubicin, Dequalinium chloride, Vincristine, Nitazoxanide, Nitrofurazone, Temsirolimus, Eltrombopag, Adapalene, Azacyclonol, Enoxacin and Raltegravir, and pharmaceutically acceptable salts thereof. Another aspect relates to compounds for use in treating or preventing a senescence-associated disease or disorder, and methods relating thereto.
    Type: Application
    Filed: May 25, 2018
    Publication date: April 23, 2020
    Inventors: Jesus GIL, Ana GUERRERO, Nicolas HARRANZ
  • Publication number: 20200121621
    Abstract: Disclosed herein are methods of treating subjects suffering from estrogen receptor positive cancer of the brain by administering a selective estrogen receptor degrader (SERM). Also disclosed are methods of treating a cancer that is resistant to an estrogen receptor modulator by administering a SERM.
    Type: Application
    Filed: December 19, 2019
    Publication date: April 23, 2020
    Inventors: Suzanne E. Wardell, Erik R. Nelson, Donald P. McDonnell
  • Publication number: 20200121622
    Abstract: A method of forming an implant in a tissue can include: providing an injectable liquid composition comprising one or more precursors of a crosslinkable composition; injecting the injectable composition into the tissue at the rate of about 10-12000 injections per minute and/or at an amount of 1.0E-02 ml to 1.0E-16 ml per injection; and crosslinking the one or more precursors of the crosslinkable composition so as to form a crosslinked composition.
    Type: Application
    Filed: December 18, 2019
    Publication date: April 23, 2020
    Inventor: Chandrashekhar P. Pathak
  • Publication number: 20200121623
    Abstract: Ketogenic compositions including a plurality of beta-hydroxybutyrate (BHB) salts and beta-hydroxybutyric acid are formulated to induce or sustain ketosis in a subject to which the ketogenic compositions are administered. The BHB composition is formulated to provide a biologically balanced set of cationic electrolytes, and is formulated to avoid detrimental health effects associated with imbalanced electrolyte ratios. A ketogenic composition includes beta-hydroxybutyric acid and a plurality of BHB salts selected from sodium, potassium, calcium, and magnesium. The BHB composition may include transition metal cations (e.g., zinc or iron), one or more BHB-amino acid salts, a short-, medium-, or long chain fatty acid source, vitamin D3, flavorant, or other excipient.
    Type: Application
    Filed: December 19, 2019
    Publication date: April 23, 2020
    Inventor: Gary Millet
  • Publication number: 20200121624
    Abstract: The present invention provides a method of administering magnesium threonate to a subject in need of supplementing magnesium. At least a portion of magnesium (Mg) and threonate (T) is present in a salt form of MgT2. The method may comprise administration of magnesium threonate at two different time points per day. The method may comprise administering, at a first time point, a first oral dosage form comprising magnesium threonate. The method may comprise administering, at a second time point, a combination of the first oral dosage form and a second oral dosage form comprising magnesium threonate. The first and second oral dosage forms may exhibit different dissolution profiles in a dissolution medium.
    Type: Application
    Filed: October 25, 2019
    Publication date: April 23, 2020
    Inventors: Guosong Liu, Fei Mao, Jason Weinger
  • Publication number: 20200121625
    Abstract: The present invention relates to a combination product and its use in therapy.
    Type: Application
    Filed: April 18, 2018
    Publication date: April 23, 2020
    Inventors: ROBERT WALCZAK, CAROLE BELANGER, VANESSA LEGRY, BENOÃŽT NOEL, EMELINE DESCAMPS, GUILLAUME VIDAL, MATHILDE WALCZAK
  • Publication number: 20200121626
    Abstract: There is provided a convenient new treatment of Parkinson disease by a frequent administration of optimal levodopa doses mimicking a continuous intravenous or infusion treatment, thus mitigating motor complications; and a new carbidopa/levodopa pharmaceutical unit form providing said new treatment.
    Type: Application
    Filed: December 18, 2019
    Publication date: April 23, 2020
    Applicant: AVION PHARMACEUTICALS, LLC
    Inventors: Thomas N. CHASE, Kathleen E. CLARENCE-SMITH
  • Publication number: 20200121627
    Abstract: The present disclosure relates to a pharmaceutical composition for preventing or treating a muscle disease, comprising, as an active ingredient, azelaic acid or a pharmaceutically acceptable salt thereof. In muscle cells, the azelaic acid according to the present disclosure can increase expression of proteins associated with muscle protein synthesis and muscle mass increase and can inhibit expression of enzymes involved in muscle protein degradation; and therefore the azelaic acid can exhibit a muscle strength-enhancing effect through muscle differentiation, muscle regeneration, and muscle mass increase in a muscle disease caused by muscle function decline, muscle wasting, or muscle degeneration. In addition, the azelaic acid can inhibit muscle decrease. Accordingly, the azelaic acid can be used for preventing or treating a muscle disease, differentiating muscles, regenerating muscles and enhancing muscles, or for increasing muscle mass, promoting muscle production, or improving muscle function.
    Type: Application
    Filed: October 16, 2019
    Publication date: April 23, 2020
    Applicant: INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY
    Inventor: Tae Sun PARK
  • Publication number: 20200121628
    Abstract: The present disclosure relates to, inter alia, methods of treating mixed dyslipidemia with ethyl eicosapentaenoate.
    Type: Application
    Filed: December 10, 2019
    Publication date: April 23, 2020
    Inventors: Ian Osterloh, Pierre Wicker, Rene Braeckman, Paresh Soni, Mehar Manku
  • Publication number: 20200121629
    Abstract: The present invention relates to a pharmaceutical composition, containing sarpogrelate or a pharmaceutically acceptable salt thereof as an active ingredient, for preventing, alleviating, or treating sensorineural hearing loss. The sarporgrelate according to the present invention protects against hearing loss caused by noise through the suppression of auditory cell apoptosis and the expression increase of antioxidant enzyme in auditory cells, and thus can be advantageously used in the prevention and alleviation of sensorineural hearing loss.
    Type: Application
    Filed: April 10, 2018
    Publication date: April 23, 2020
    Inventors: Yun-Hoon CHOUNG, Young Sun KIM, Young-Joon PARK
  • Publication number: 20200121630
    Abstract: In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof.
    Type: Application
    Filed: December 13, 2019
    Publication date: April 23, 2020
    Inventors: Ian Osterloh, Pierre Wicker, Rene Braeckman, Paresh Soni, Mehar Manku
  • Publication number: 20200121631
    Abstract: The present invention includes surprisingly water-soluble salts of a phenylalkylamine compound that are potent antagonists of L-type calcium channels. Aqueous solutions including salts of the instant invention are formulated for nasal administration and provide a novel therapeutic platform for the treatment of stable angina, migraine, and cardiac arrhythmia, such as paroxysmal supraventricular tachycardia.
    Type: Application
    Filed: December 19, 2019
    Publication date: April 23, 2020
    Inventor: Martin P. Maguire
  • Publication number: 20200121632
    Abstract: Certain embodiments of the invention pertain to a method of treating an infection in a subject caused by an infectious agent other than Escherichia coli, the method comprising administering to the subject arsinothricin or a salt thereof. The infectious agent other than E. coli can be a bacterium, protozoan, helminth, archaebacterium, or a fungus. In preferred embodiments, the infectious agent is Mycobacterium tuberculosis, Mycobacterium brevis, or Enterobacter cloacae. The invention also pertains to a method of treating an infection in a subject caused by an infectious agent, comprising administering to the subject arsinothricin or a salt thereof in combination with an inhibitor of phosphinothricin N-acetyltransferase or arsinothricin N-acetyltransferase. In certain such embodiments, the infectious agent expresses phosphinothricin N-acetyltransferase or arsinothricin N-acetyltransferase.
    Type: Application
    Filed: October 17, 2018
    Publication date: April 23, 2020
    Applicant: The Florida International University Board of Trustees
    Inventors: Barry Philip ROSEN, Masafumi YOSHINAGA
  • Publication number: 20200121633
    Abstract: The disclosed subject matter provides N-substituted hydroxylamine derivative compounds, pharmaceutical compositions and kits comprising such compounds, and methods of using such compounds or pharmaceutical compositions. In particular, the disclosed subject matter provides methods of using such compounds or pharmaceutical compositions for treating heart failure.
    Type: Application
    Filed: December 23, 2019
    Publication date: April 23, 2020
    Inventors: Vincent Jacob Kalish, Frederick Arthur Brookfield, Stephen Martin Courtney, Lisa Marie Frost, John P. Toscano
  • Publication number: 20200121634
    Abstract: The present invention relates to a pharmaceutical composition for preventing or treating allergic diseases such as asthma or atopy including baicalein as an active ingredient. Baicalein is capable of regulating thymic stromal lymphopoietin-mediated signal transduction. The pharmaceutical composition of the present invention can effectively suppress inflammatory responses of allergic or asthmatic diseases due to the presence of baicalein extracted from Scutellariae Radix that regulates TSLP-mediated intracellular signal transduction to inhibit intracellular phosphorylation of STATS and inhibit the binding of TSLP to TSLPR. In addition, the pharmaceutical composition of the present invention may further include one or more compounds having synergistic effects with baicalein. In this case, the pharmaceutical composition can more effectively suppress inflammatory responses of allergic diseases such as asthma or atopy.
    Type: Application
    Filed: January 4, 2018
    Publication date: April 23, 2020
    Applicant: Korea University Research and Business Foundation, Sejong Campus
    Inventors: Ki Yong LEE, Young Ho JEON, Youngjoo BYUN, Kiho LEE, Yong Woo JUNG
  • Publication number: 20200121635
    Abstract: Provided herein is a pharmaceutical composition comprising an isoflavonoid derivative and a cyclodextrin. Also provided herein are methods of treating cancer, sensitizing cancer cells, and inducing apoptosis in cancer cells by administering such compositions. In specific instances, provided herein are intravenous compositions and therapies.
    Type: Application
    Filed: June 18, 2019
    Publication date: April 23, 2020
    Inventor: Ofir MORENO
  • Publication number: 20200121636
    Abstract: Presented herein are methods for treating bile acid diarrhea, short bowel syndrome (SBS), and cholecystectomy-associated diarrhea by administering to a patient in need thereof, an inhibitor of chloride-ion transport in an amount sufficient to treat diarrhea. In particular embodiments, infants, and juveniles with SBS are treated with an inhibitor of chloride-ion transport in an amount sufficient to treat diarrhea. Treatment of diarrhea includes the treatment of the diarrhea as well as the pain, abdominal discomfort and other symptoms associated with diarrhea. In one embodiment, the inhibitor of chloride-ion transport is crofelemer.
    Type: Application
    Filed: May 31, 2018
    Publication date: April 23, 2020
    Inventors: Lisa A. Conte, Pravin R. Chaturvedi, Charles Conte
  • Publication number: 20200121637
    Abstract: This disclosures relates to new compositions and methods for making cannabinoid formulations. In one embodiment, this disclosure provides water soluble compositions comprising a first purified cannabinoid and Vitamin E TPGS. In one embodiment, the disclosure herein comprises a method of making powders comprising heatings material to a first temperature and a second temperature.
    Type: Application
    Filed: December 2, 2019
    Publication date: April 23, 2020
    Applicant: CANOPY GROWTH CORPORATION
    Inventor: Kurt Aron Levy
  • Publication number: 20200121638
    Abstract: Formulations for topical use based on vitamin E or an ester thereof for use in removing, reducing or inhibiting a bacterial and/or fungal biofilm, are disclosed. The ester of vitamin E is an ester with a carboxylic acid of formula R—COOH, in which R is an alkyl radical having from 1 to 19 carbon atoms, or an alkenyl or alkynyl having from 2 to 19 carbon atoms.
    Type: Application
    Filed: November 14, 2019
    Publication date: April 23, 2020
    Applicant: BIO.LO.GA. S.R.L.
    Inventor: Giorgio PANIN
  • Publication number: 20200121639
    Abstract: The present invention is drawn to methods for effecting weight loss, e.g.. in the treatment of obesity and related conditions, including conditions associated with and/or caused by obesity per se.
    Type: Application
    Filed: March 2, 2018
    Publication date: April 23, 2020
    Inventors: Deborah Lynn Keefe, Qing SHAO
  • Publication number: 20200121640
    Abstract: The present invention relates to stable therapeutic compositions of pharmaceutical grade acids and pH buffering agents. The present invention also is directed to methods of treatment for mitochondrial disorders, metabolic conditions, diabetic conditions, and cardiovascular conditions, by administration of compositions of the present disclosure.
    Type: Application
    Filed: October 28, 2019
    Publication date: April 23, 2020
    Applicant: Reven, LLC
    Inventors: James Ervin, Hendrik J. Van Wyk, Brian D. Denomme, Mariette L. Van Wyk, Peter Pacult, Michael A. Volk
  • Publication number: 20200121641
    Abstract: Methods for inhibiting cell growth, inhibiting DNA polymerase activity, and inhibiting DNA replication and repair are provided. In a method of inhibiting cell growth, a cell, such as a cancer cell, is contacted with zelpolib or a derivative or pharmaceutically acceptable salt thereof. The cell growth can be inhibited in vivo, and in certain embodiments, the cell growth is inhibited in vitro. In a method for inhibiting DNA polymerase activity, a DNA polymerase is contacted with zelpolib or a derivative or pharmaceutically acceptable salt thereof. In certain embodiments, the DNA polymerase is Pol ?. In a method for inhibiting DNA replication and repair, a cell, such as a cancer cell, is contacted with zelpolib or a derivative or pharmaceutically acceptable salt thereof. The DNA replication and repair can be inhibited in vivo, and in certain embodiments, the DNA replication and repair is inhibited in vitro.
    Type: Application
    Filed: October 21, 2019
    Publication date: April 23, 2020
    Inventor: Zhongtao ZHANG
  • Publication number: 20200121642
    Abstract: Activating transcription factor 6 (ATF6) is involved in cystic fibrosis transmembrane conductance regulator (CFTR) repression and understanding this inhibitory mechanism is of great interest to develop a therapeutic approach based on UPR regulation. Using site-1 protease (S1P) inhibitor (e.g. PF-429242) the inventors showed that both membrane localization and function of F508del-CFTR are partially restored. Accordingly, the present invention relates to a method of treating a disease associated with reduced CFTR function in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a S1P inhibitor.
    Type: Application
    Filed: April 20, 2018
    Publication date: April 23, 2020
    Inventors: PASCAL TROUVE, CLAUDE FEREC, MATHIEU KERBIRIOU, FLORENTIN HUGUET
  • Publication number: 20200121643
    Abstract: Topical formulations comprising soft glycopyrrolates are useful for treating excessive sweating conditions in subjects, such as humans suffering from hyperhidrosis. Preferably, at least one soft anticholinergic agent is provided in an effective amount or concentration in an anhydrous formulation that can inhibit excessive perspiration resulting from a condition such as hyperhidrosis.
    Type: Application
    Filed: December 5, 2019
    Publication date: April 23, 2020
    Inventors: Nicholas S. BODOR, John J. KOLENG, David ANGULO
  • Publication number: 20200121644
    Abstract: Methods of treating sepsis induced acute brain dysfunction (SiBD), comprising administering a synaptic vesicle 2a and/or 2b binding chemical entity to a subject with sepsis. Methods of reducing sepsis mortality, comprising administering a synaptic vesicle 2a and/or 2b binding chemical entity to a subject with sepsis. In some embodiments the synaptic vesicle 2a and/or 2b binding chemical entity is a synaptic vesicle 2a and/or 2b modulator such as agonist, partial agonist, antagonist or partial antagonist. In some embodiments the synaptic vesicle 2a and/or 2b binding chemical entity is levetiracetam or a derivative or analogue of levetiracetam. In some embodiments the synaptic vesicle 2a binding chemical entity is levetiracetam.
    Type: Application
    Filed: May 19, 2017
    Publication date: April 23, 2020
    Inventors: Tarek SHARSHAR, Fabrice CHRETIEN, Aurelien MAZERAUD, Fernando Augusto BOZZA
  • Publication number: 20200121645
    Abstract: Disclosed is a composition and method for preventing, ameliorating or treating an EGFR-mutant non-small cell lung cancer including a c-Jun N-terminal kinase (JNK) activator as an active ingredient. The composition significantly reduces the level of EGFR in EGFR-mutant non-small cell lung cancer cells, inducing apoptosis. Therefore, the composition is suitable for preventing, ameliorating or treating non-small cell lung cancers in subjects in need thereof. Particularly, the composition is effective in treating and preventing non-small cell lung cancers, which are difficult to effectively treat and prevent with gefitinib or erlotinib. Also disclosed is a composition and method for inhibiting the resistance of a non-small cell lung cancer to an EGFR tyrosine kinase inhibitor including a c-Jun N-terminal kinase (JNK) activator as an active ingredient. The inhibitory composition effectively overcomes resistance to EGFR tyrosine kinase inhibitors.
    Type: Application
    Filed: February 13, 2019
    Publication date: April 23, 2020
    Applicants: THE ASAN FOUNDATION, University of Ulsan Foundation For Industry Cooperation
    Inventors: Jaekyoung SON, Jin Kyung RHO, Jae Cheol LEE
  • Publication number: 20200121646
    Abstract: The present application discloses chemical compositions and methods for enhancing the transdermal permeation of therapeutic agents through skin. The chemical compositions and methods of the invention can include combinations of a first fatty acid having about 14 or more carbon atoms and a second fatty acid having about 10 or less carbon atoms. These compositions are useful for the delivery of therapeutic agents, in particular hard to deliver drugs such as those that have fused rings, including ondansetron, and large drugs such as peptides. The compositions of the invention can be formulated as transdermal gels, lotions, creams, transdermal patches, sprays or mists.
    Type: Application
    Filed: December 17, 2019
    Publication date: April 23, 2020
    Inventors: Kirti H. Valia, Agis Kydonieus
  • Publication number: 20200121647
    Abstract: The present invention relates to substituted indoline derivatives, methods to prevent or treat dengue viral infections by using said compounds and also relates to said compounds for use as a medicine, more preferably for use as a medicine to treat or prevent dengue viral infections. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the compounds, to the compositions or preparations for use as a medicine, more preferably for the prevention or treatment of dengue viral infections. The invention also relates to processes for preparation of the compounds.
    Type: Application
    Filed: March 29, 2018
    Publication date: April 23, 2020
    Applicants: JANSSEN PHARMACEUTICALS, INC., KATHOLIEKE UNIVERSITEIT LEUVEN
    Inventors: Bart Rudolf Romanie Kesteleyn, Jean-François Bonfanti, Erwin Coesemans, Pierre Jean-Marie Bernard Raboisson, Arnaud Didier M Marchand, Dorothée Alice Marie-Eve Bardiot
  • Publication number: 20200121648
    Abstract: Provided is a pharmaceutical composition which contains pemafibrate, a salt thereof or a solvate thereof and one or more selected from the group consisting of a metal oxide, a dihydric alcohol, an ester species and a silicic acid compound and which has excellent storage stability. The pharmaceutical composition includes the following components (A) and (B): (A) pemafibrate, a salt thereof or a solvate thereof; and (B) one or more selected from the group consisting of the following components (B-1) to (B-4): (B-1) a metal oxide; (B-2) a dihydric alcohol; (B-3) an ester species; and (B-4) a silicic acid compound, with component (A) and component (B) being substantially in non-contact with each other.
    Type: Application
    Filed: June 29, 2018
    Publication date: April 23, 2020
    Applicant: KOWA COMPANY, LTD.
    Inventor: Akito MINAMIZONO
  • Publication number: 20200121649
    Abstract: Provided is a novel technique for improving storage stability of a pharmaceutical composition containing pemafibrate, a salt thereof or a solvate thereof and a cellulose species. A pharmaceutical preparation obtained by storing a pharmaceutical composition containing the following components (A) and (B) in a tight package: (A) pemafibrate, a salt thereof or a solvate thereof; and (B) a cellulose species.
    Type: Application
    Filed: June 29, 2018
    Publication date: April 23, 2020
    Applicant: KOWA COMPANY, LTD.
    Inventors: Shin SUGIMOTO, Akito MINAMIZONO